Literature DB >> 24175209

Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Massimo De Paschale1, Pierangelo Clerici.   

Abstract

Serological tests for antibodies specific for Epstein-Barr virus (EBV) antigens are frequently used to define infection status and for the differential diagnosis of other pathogens responsible for mononucleosis syndrome. Using only three parameters [viral capsid antigen (VCA) IgG, VCA IgM and EBV nuclear antigen (EBNA)-1 IgG],it is normally possible to distinguish acute from past infection: the presence of VCA IgM and VCA IgG without EBNA-1 IgG indicates acute infection, whereas the presence of VCA IgG and EBNA-1 IgG without VCA IgM is typical of past infection. However, serological findings may sometimes be difficult to interpret as VCA IgG can be present without VCA IgM or EBNA-1 IgG in cases of acute or past infection, or all the three parameters may be detected simultaneously in the case of recent infection or during the course of reactivation. A profile of isolated EBNA-1 IgG may also create some doubts. In order to interpret these patterns correctly, it is necessary to determine IgG avidity, identify anti-EBV IgG and IgM antibodies by immunoblotting, and look for heterophile antibodies, anti-EA (D) antibodies or viral genome using molecular biology methods. These tests make it possible to define the status of the infection and solve any problems that may arise in routine laboratory practice.

Entities:  

Keywords:  Avidity IgG; Epstein-Barr virus infection; Epstein-Barr virus-DNA; Immunoblotting; Serology

Year:  2012        PMID: 24175209      PMCID: PMC3782265          DOI: 10.5501/wjv.v1.i1.31

Source DB:  PubMed          Journal:  World J Virol        ISSN: 2220-3249


  123 in total

Review 1.  Persistence of the Epstein-Barr virus and the origins of associated lymphomas.

Authors:  David A Thorley-Lawson; Andrew Gross
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.

Authors:  Q Y Yao; A B Rickinson; M A Epstein
Journal:  Int J Cancer       Date:  1985-01-15       Impact factor: 7.396

Review 3.  Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology.

Authors:  G Bauer
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

4.  Acute Epstein-Barr virus infections in children.

Authors:  H Schmitz; D Volz; C Krainick-Riechert; M Scherer
Journal:  Med Microbiol Immunol       Date:  1972       Impact factor: 3.402

Review 5.  Epstein-Barr virus and post-transplant lymphoproliferative disease.

Authors:  R D Holmes; R J Sokol
Journal:  Pediatr Transplant       Date:  2002-12

6.  Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.

Authors:  Servi J C Stevens; Paul H M Smits; Sandra A W M Verkuijlen; Davy A P Rockx; Eric C M van Gorp; Jan W Mulder; Jaap M Middeldorp
Journal:  AIDS       Date:  2007-10-18       Impact factor: 4.177

7.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

8.  Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method.

Authors:  Barbara C Gärtner; Ralf D Hess; Dirk Bandt; Alexander Kruse; Axel Rethwilm; Klaus Roemer; Nikolaus Mueller-Lantzsch
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

9.  Comparative evaluation of the use of immunoblots and of IgG avidity assays as confirmatory tests for the diagnosis of acute EBV infections.

Authors:  J Schubert; W Zens; B Weissbrich
Journal:  J Clin Virol       Date:  1998-12       Impact factor: 3.168

10.  Serological survey of nasopharyngeal carcinoma in 21 cities of south China.

Authors:  H Deng; Y Zeng; Y Lei; Z Zhao; P Wang; B Li; Z Pi; B Tan; Y Zheng; W Pan
Journal:  Chin Med J (Engl)       Date:  1995-04       Impact factor: 2.628

View more
  65 in total

1.  Solving Summer Fever in Early Pregnancy.

Authors:  Traci Fraser; William Hillmann; Philip A Lederer; Anne Kasmar; Joseph Rencic
Journal:  J Gen Intern Med       Date:  2015-04-28       Impact factor: 5.128

2.  Maternal Antibodies to Herpes Virus Antigens and Risk of Gastroschisis in Offspring.

Authors:  Martha M Werler; Samantha E Parker; Klaus Hedman; Mika Gissler; Annukka Ritvanen; Heljä-Marja Surcel
Journal:  Am J Epidemiol       Date:  2016-11-17       Impact factor: 4.897

3.  Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology.

Authors:  Julia Simon; Zhiwei Liu; Allan Hildesheim; Tim Waterboer; Nicole Brenner; Kelly J Yu; Wan-Lun Hsu; Cheng-Ping Wang; Yin-Chu Chien; Anna E Coghill; Chien-Jen Chen; Julia Butt; Carla Proietti; Denise L Doolan
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

4.  Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: diagnostic potential of O-glycopeptide microarrays.

Authors:  Isotta D'Arrigo; Emiliano Cló; Tomas Bergström; Sigvard Olofsson; Ola Blixt
Journal:  Glycoconj J       Date:  2013-01-08       Impact factor: 2.916

5.  Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with Plasmodium falciparum Malaria during Pregnancy.

Authors:  Sidney Ogolla; Ibrahim I Daud; Amolo S Asito; Odada P Sumba; Collins Ouma; John Vulule; Jaap M Middeldorp; Arlene E Dent; Saurabh Mehta; Rosemary Rochford
Journal:  Clin Vaccine Immunol       Date:  2015-09-16

6.  Facial nerve palsy secondary to Epstein-Barr virus infection of the middle ear in pediatric population may be more common than we think.

Authors:  Katarina Vogelnik; Aleš Matos
Journal:  Wien Klin Wochenschr       Date:  2017-09-18       Impact factor: 1.704

7.  Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.

Authors:  Xiaoyun Lin; Shao Chen; Xiangyang Xue; Lijun Lu; Shanli Zhu; Wenshu Li; Xiangmin Chen; Xiaozhi Zhong; Pengfei Jiang; Torsoo Sophia Sename; Yi Zheng; Lifang Zhang
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

8.  T cell epitope screening of Epstein-Barr virus fusion protein gB.

Authors:  Haiwen Chen; Xiao Zhang; Shanshan Zhang; Xiaobing Duan; Tong Xiang; Xiang Zhou; Wanlin Zhang; Xinyu Zhang; Qisheng Feng; Yinfeng Kang; Jiangping Li; Lan Deng; Liang Wang; Xing Lv; Musheng Zeng; Yi-Xin Zeng; Miao Xu
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

9.  Early Disseminated Lyme Disease Causing False-Positive Serology for Primary Epstein-Barr Virus Infection: Report of 2 Cases.

Authors:  Adriana J Pavletic; Adriana R Marques
Journal:  Clin Infect Dis       Date:  2017-07-15       Impact factor: 9.079

10.  Epstein-Barr virus is related with 5-aminosalicylic acid, tonsillectomy, and CD19(+) cells in Crohn's disease.

Authors:  Juan C Andreu-Ballester; Rafael Gil-Borrás; Carlos García-Ballesteros; Ignacio Catalán-Serra; Victoria Amigo; Virgina Fernández-Fígares; Carmen Cuéllar
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.